Santen Pharmaceutical Co Ltd 2022 Integrated Report
The report presents Santen's FY2021 performance for the year ended March 31, 2022, including consolidated revenue of JPY 266.3 billion and 4,315 employees. It details ESG materialities and progress, including a 50% Scope 1 and 2 emissions reduction target by 2030 from 2019 and SBTi approval of that target. It also discloses support for TCFD recommendations, climate scenario analysis, renewable-energy conversion at Japanese plants, and biomass-plastic initiatives. Governance highlights include a seven-member Board with two women and 71% outside directors.
Company: Santen Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2022
Type: Integrated Report
Pages: 85
Back to company
Santen Pharmaceutical Co Ltd
Santen Report
The report presents Santen's FY2021 performance for the year ended March 31, 2022, including consolidated revenue of JPY 266.3 billion and 4,315 employees. It details ESG materialities and progress, including a 50% Scope 1 and 2 emissions reduction target by 2030 from 2019 and SBTi approval of that target. It also discloses support for TCFD recommendations, climate scenario analysis, renewable-energy conversion at Japanese plants, and biomass-plastic initiatives. Governance highlights include a seven-member Board with two women and 71% outside directors.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Apr 1, 2021 - Mar 31, 2022
Fiscal Year
2021
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Net Zero Target
Employees